logo BDSP

Base documentaire

  1. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria.

    Article - En anglais

    This study estimated the cost-effectiveness of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in Austria, as well as the costs related to the discontinuation of antidepressant treatment from the perspective of the Austrian Sick Funds (Gebietskrankenkassen).

    The economic analyses were based on a meta-analysis of four randomised clinical trials comparing mirtazapine with amitriptyline, and on a six week comparative trial of mirtazapine and fluoxetine which was extrapolated to six months using assumptions derived from the literature.

    Decision models of the treatment paths and associated resource use attributable to managing moderate and severe depression in Austria were developed from clinical trial data, information on Austrian clinical practice obtained from interviews with an Austrian Delphi panel (comprising psychiatrists and GPs), and from published literature.

    The models were used to estimate the expected costs to the Gebietskrankenkassen of managing a patient with moderate or severe depression, and the indirect cost per patient to Austrian society due to lost productivity.

    The expected cost to the Gebietskrankenkassen of healthcare resource use attributable to managing a patient suffering from moderate or severe depression who discontinues antidepressant treatment was estimated to be ATS 4,088 over five months, of which hospitalisations accounted for nearly 69% of the cost. (...)

    Mots-clés Pascal : Etat dépressif, Traitement, Chimiothérapie, Antidépresseur, Psychotrope, Analyse coût, Fluoxétine, Inhibiteur recapture, Sérotonine, Amitriptyline, Etude comparative, Mirtazapine, Santé mentale, Autriche, Europe, Homme, Economie santé, Composé tricyclique, Trouble humeur

    Mots-clés Pascal anglais : Depression, Treatment, Chemotherapy, Antidepressant agent, Psychotropic, Cost analysis, Fluoxetine, Reuptake inhibitor, Serotonin, Amitriptyline, Comparative study, Mirtazapine, Mental health, Austria, Europe, Human, Health economy, Tricyclic compound, Mood disorder

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0388851

    Code Inist : 002B02B02. Création : 22/03/2000.